[ad_1]
ANI | , Posted by Taptrisha DasWashington
Researchers at Tulane University have discovered a promising new strategy for treating the persistent neurological symptoms associated with Lyme disease, providing hope to patients who continue to suffer from the bacterial infection even after receiving antibiotic treatment.
The findings were published in Frontiers in Immunology.
Lyme disease, caused by the bacteria Borrelia burgdorferi and spread by tick bites, can cause a variety of symptoms, including those affecting the central and peripheral nervous systems.
While medications can effectively treat the infection in most cases, a portion of people continue to have symptoms such as memory loss, fatigue, and pain – a condition known as Lyme disease syndrome after treatment.
Principal investigator Geeta Parthasarathy, PhD, assistant professor of microbiology and immunology at the Tulane National Primate Research Center, has found that fibroblast growth factor receptor inhibitors, a type of drug previously studied in the context of cancer, significantly reduce inflammation and cell death. Can reduce. In brain and nerve tissue samples infected with Borrelia burgdorferi.
This finding suggests that targeting FGFR pathways may offer an exciting new therapeutic approach to address persistent neuroinflammation in patients with Lyme disease syndrome after treatment.
“Our findings open the door to new research approaches that may help us support patients suffering from the lasting effects of Lyme disease,” said Parthasarathy.
“By focusing on the underlying inflammation that contributes to these symptoms, we hope to develop treatments that can improve the quality of life for people affected by this debilitating condition.”
This story is published from a wire agency feed without any modifications to the text. Only the headline has been changed.
[ad_2]
